Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics

2016 ◽  
Vol 8 (6) ◽  
pp. 697-711 ◽  
Author(s):  
Michela Rosini ◽  
Elena Simoni ◽  
Roberta Caporaso ◽  
Anna Minarini
Talanta ◽  
2020 ◽  
Vol 211 ◽  
pp. 120700 ◽  
Author(s):  
Pedro Carneiro ◽  
Simone Morais ◽  
Maria do Carmo Pereira

2021 ◽  
Vol 14 (1) ◽  
pp. 33
Author(s):  
Marta Campora ◽  
Valeria Francesconi ◽  
Silvia Schenone ◽  
Bruno Tasso ◽  
Michele Tonelli

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline leading to dementia and death. AD imposes neuronal death by the intricate interplay of different neurochemical factors, which continue to inspire the medicinal chemist as molecular targets for the development of new agents for the treatment of AD with diverse mechanisms of action, but also depict a more complex AD scenario. Within the wide variety of reported molecules, this review summarizes and offers a global overview of recent advancements on naphthoquinone (NQ) and anthraquinone (AQ) derivatives whose more relevant chemical features and structure-activity relationship studies will be discussed with a view to providing the perspective for the design of viable drugs for the treatment of AD. In particular, cholinesterases (ChEs), β-amyloid (Aβ) and tau proteins have been identified as key targets of these classes of compounds, where the NQ or AQ scaffold may contribute to the biological effect against AD as main unit or significant substructure. The multitarget directed ligand (MTDL) strategy will be described, as a chance for these molecules to exhibit significant potential on the road to therapeutics for AD.


Cells ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 2347
Author(s):  
Anna Atlante ◽  
Giuseppina Amadoro ◽  
Antonella Bobba ◽  
Valentina Latina

A new epoch is emerging with intense research on nutraceuticals, i.e., “food or food product that provides medical or health benefits including the prevention and treatment of diseases”, such as Alzheimer’s disease. Nutraceuticals act at different biochemical and metabolic levels and much evidence shows their neuroprotective effects; in particular, they are able to provide protection against mitochondrial damage, oxidative stress, toxicity of β-amyloid and Tau and cell death. They have been shown to influence the composition of the intestinal microbiota significantly contributing to the discovery that differential microorganisms composition is associated with the formation and aggregation of cerebral toxic proteins. Further, the routes of interaction between epigenetic mechanisms and the microbiota–gut–brain axis have been elucidated, thus establishing a modulatory role of diet-induced epigenetic changes of gut microbiota in shaping the brain. This review examines recent scientific literature addressing the beneficial effects of some natural products for which mechanistic evidence to prevent or slowdown AD are available. Even if the road is still long, the results are already exceptional.


2010 ◽  
Vol 1 (2) ◽  
pp. 293-303 ◽  
Author(s):  
Iris Grossman ◽  
Michael W. Lutz ◽  
Donna G. Crenshaw ◽  
Ann M. Saunders ◽  
Daniel K. Burns ◽  
...  

Nature ◽  
2016 ◽  
Vol 539 (7628) ◽  
pp. 187-196 ◽  
Author(s):  
Rebecca G. Canter ◽  
Jay Penney ◽  
Li-Huei Tsai

Sign in / Sign up

Export Citation Format

Share Document